ERICA-02 Study : impact of Physical Exercise on the Tumor Immune Microenvironment in Patients Treated With Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer

Recent advances combining chemotherapy and immunotherapy before surgery havesignificantly improved outcomes for patients with resectable non‐small cell lung cancer(NSCLC). However, a substantial proportion of patients still do not respond optimally tothese treatments. Researchers believe that physical activity may help strengthen theimmune system and favorably modify the tumor microenvironment, potentially improvingtreatment effectiveness. ERICA‐02 aims to investigate this hypothesis.The primaryobjective of ERICA‐02 is to evaluate whether a structured exercise program performedduring neoadjuvant chemo‐immunotherapy can increase the presence of CD8+ cytotoxic Tlymphocytes within the tumor. These immune cells play a key role in recognizing anddestroying cancer cells and are considered an important marker of anti‐tumor immuneresponse.The study is designed for adults with locally advanced, resectable non‐smallcell lung cancer who are eligible for neoadjuvant chemo‐immunotherapy followed bysurgery. Participants must be medically fit to engage in physical activity, able tocomply with study procedures, and provide informed consent before enrollment.ERICA‐02 isa multicenter, randomized phase II pilot trial involving approximately 40 patients.Participants will be randomly assigned to one of two groups : intervention group andcontrol group. Each participant will be involved in the study for approximately sixmonths, including three months of exercise intervention for patients assigned to theexercise group.